Atlas Trials

Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis

Clinical trial NCT02609022 · COMPLETED

Trial details

NCT number
NCT02609022
Sponsor
CuraVac
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myasthenia Gravis
Start date
2016-03-01
Primary completion
2018-09-30
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.